

EXHIBIT A

1:15-cv-07488-CM-RWL
Forest's Phase 1 Exhibit List

Trial Ex. No.	Dep. Ex. #	Beg Bates	End Bates	Date	Doc Description	Objections	Includes Electronic File(s)
DTX-001	Green Ex. 3	FRX-AT-04617640	FRX-AT-04617646	1/19/2010	Email: "FW: Mylan Mtg Next Week"		Yes
DTX-002		FRX-AT-04617585	FRX-AT-04617587	1/14/2010	Email: "Re: Authorized Generic Lexapro / Mylan"		
DTX-003		FRX-AT-04617480	FRX-AT-04617480	7/22/2009	Email: "RE: Mylan"		
DTX-004		FRX-AT-04617599	FRX-AT-04617604	1/14/2010	Email: "RE: Authorized Generic Lexapro / Mylan"		
DTX-005		FRX-AT-04617606	FRX-AT-04617612	1/14/2010	Email: "RE: Authorized Generic Lexapro / Mylan"		Yes
DTX-006		FRX-AT-04617613	FRX-AT-04617616	1/15/2010	Email: "FW: Lexapro analysis"		
DTX-007	Mears Ex. 15	FRX-AT-04447018	FRX-AT-04447019	10/18/2007	Email: "Impact of DRA on Authorized Generics"		
DTX-008		FRX-AT-04617528	FRX-AT-04617530	1/7/2010	Email: "Lexapro Generic Analysis"		
DTX-009	Green Ex. 11	FRX-AT-04617114	FRX-AT-04617114	3/18/2010	Excel: "Lexapro Generic Analysis HS - Mylan 40% Share - Wt COGS 03 2010 Years 1 and 2 (70-30 Split) with Lundbeck Share.xls"		Yes
DTX-010	Bruno Ex. 13 Green Ex. 10	FRX-AT-04617115	FRX-AT-04617115	3/17/2010	Excel: "Lexapro Generic Analysis HS - Mylan 40% Share - Wt COGS 03 2010 Years 1 and 2 (70-30 Split).xls"		Yes
DTX-011		FRX-AT-04617764	FRX-AT-04617768	3/16/2010	Email: "RE: Lexapro Best Price Analysis - Year 2"		Yes
DTX-012	Bruno Ex. 3 Carnevale Ex. 13 Agovino Ex. 15 Mears Ex. 4	FRX-AT-00000253	FRX-AT-00000273	10/3/2005	Document: Original Lexapro Agreement		
DTX-013	Bruno Ex. 4 Curia Ex. 3 Solomon Ex. 9	FRX-AT-00000464	FRX-AT-00000477	7/21/2010	Document: Amendment to Distribution and Supply Agreement (Generic Lexapro)		
DTX-014		FRX-AT-04628179	FRX-AT-04628191	8/19/2009	Document: Cost Sharing Agreement - Lundbeck and Forest		
DTX-015	McCormick (DRL) Ex. 10 Johnston Ex. 10	N/A	N/A	7/2/2009	Document: Report and Recommendation Regarding Claim Construction, <i>Forest Laboratories Inc., ET AL., v. Cobalt Laboratories Inc., ET AL.</i> , DE373, No. 08-21 (D. Del.)	403	
DTX-016	Johnston Ex. 11	N/A	N/A	9/21/2009	Memorandum and Order re Report and Recommendation on Claim Construction, <i>Forest Labs., Inc., et al., v. Cobalt Labs., Inc., et al.</i> , No. 08-cv-00021, Dkt. 426 (D. Del.).	403	
DTX-018	Schneider Ex. 4	N/A	N/A	N/A	5,061,703 Patent Reexam File History		
DTX-019		FRX-AT-04228504	FRX-AT-04228556	10/30/2009	Document: Defendant Mylan Pharmaceuticals Inc.'s Supplemental Responses and Objections to Plaintiffs' First Set of Collective Interrogatories To Defendants (NOS. 1-4), <i>Forest Labs., Inc., et al., v. Cobalt Labs., Inc., et al.</i> , No. 08-cv-00021 (D. Del.)	802, 403, 602, no verification	
DTX-020		MYLMEMA_001181	MYLMEMA_001210	Oct-08	Document: Mylan - Final Labeling Text - Memantine Hydrochloride Tablets 5 mg and 10 mg		
DTX-021		MNAT_00000001	MNAT_00000301		Joint Pretrial Order		
DTX-023		KE00000302	KE00000333	8/11/2009	Email: "FW: Forest Labs, et al. v. Apotex, et al."	402, 901, CUM MIL	
DTX-051	Gupta (Amneal) Ex. 17	AMNEAL00000001	AMNEAL00000001	10/31/2009	Document: "Billing Report"	402	
DTX-058	Gupta (Amneal) Ex. 3	AMNEAL0001868	AMNEAL0001872	10/16/2007	Document: "Application Form: FDA 356h"		
DTX-059	Gupta (Amneal) Ex. 12	AMNEAL0008398	AMNEAL0008399	Feb-15	Document: Forecast		
DTX-061	Gupta (Amneal) Ex. 11	AMNEAL0008432	AMNEAL0008433	May-14	Document: Forecast		
DTX-062		DRL (Namenda AT Litig)0001232	DRL (Namenda AT Litig)0001234	10/16/2007	Letter: "Re: Memantine Hydrochloride Tablets, 5mg and 10mg Abbreviated New Drug Application"		
DTX-068	McCormick (DRL) Ex. 8	DRL (Namenda AT Litig)0001782	DRL (Namenda AT Litig)0001797	2015	Document: DRL Forecast		
DTX-071	McCormick (DRL) Ex. 34 Agovino Ex. 26	DRLNAM000010	DRLNAM000011	8/10/2010	Letter: "Re: Namenda Patent Litigation"	402, 403 MIL	
DTX-083	Mears Ex. 16 Wilk Ex. 20	FRX-AT-00000417	FRX-AT-00000427	3/23/2010	Document: "Development and Supply Agreement Between Orchid and Forest for Cefaroline - Binding Term Sheet"		
DTX-130		FRX-AT-01710620	FRX-AT-01710663	6/28/2000	Document: Merz-Forest License and Cooperation Agreement		

In re: ~~Namenda~~ Direct Purchaser Antitrust Litigation
 1:15-cv-07488-CM-RWL
 Forest's Phase 1 Exhibit List

Trial Ex. No.	Dep. Ex. #	Beg Bates	End Bates	Date	Doc Description	Objections	Includes Electronic File(s)
DTX-161	Harper (Mylan-NYAG) Ex. 10	FRX-AT-01750221	FRX-AT-01750221	Oct-14	Document: Mylan Forecast		
DTX-164	Harper (Mylan-NYAG) Ex. 14	FRX-AT-01750249	FRX-AT-01750394	2/27/2014	Document: "Mylan Inc. Form 10-K (Annual Report)"		
DTX-177	DX782 (NYAG Hearing)	FRX-AT-01784879	FRX-AT-01784882	10/16/2003	Letter: Forest NDA Approval Letter		
DTX-186		FRX-AT-01897553	FRX-AT-01897559	6/11/2012	Article: "Generics Killing Each Other on Price"	802, 402	
DTX-193		FRX-AT-02177815	FRX-AT-02177999	12/6/1989	Letter: "Re: IND 33,392 Memantine Sponsor: Merz & Co. GmbH & Co."		
DTX-194	Bray (2009) Ex. 10	FRX-AT-02178057	FRX-AT-02178432	4/29/1991	Document: "IND 33,392 Memantine Annual Report"		
DTX-195	Bray (2009) Ex. 4	FRX-AT-02191000	FRX-AT-02191002	1/13/1994	Letter: "Re: IND 33,392/Memantine Other: Inactivation of IND"		
DTX-196	Rosen Ex. 9	FRX-AT-02300444	FRX-AT-02300755	12/6/2002	Document: "Memantine HCL NDA # 21-487: Integrated Summary of Safety"		
DTX-199	Rosen Ex. 8	FRX-AT-02399093	FRX-AT-02399094	6/5/2007	Document: Federal Register Entry entitled "Determination of Regulatory Review Period for Purposes of Patent Extension: NAMENDA."		
DTX-202		FRX-AT-02660062	FRX-AT-02660064	12/19/2002	Letter: "Re: NDA 21-487/Memantine HCl Original New Drug Application"		
DTX-238		FRX-AT-03522446	FRX-AT-03522454	4/30/2008	Document: "Letter and Term Sheet between Dobfar and Forest Laboratories Ireland Limited related to Ceftaroline Development and Supply"	402, 403	
DTX-245		FRX-AT-03605359	FRX-AT-03605403	7/7/2011	Document: "Proposed Pediatric Study Request"		
DTX-246		FRX-AT-03606011	FRX-AT-03606022	1/25/2012	Letter: Proposed Pediatric Study Request for Namenda		
DTX-254	Agovino Ex. 17 McCormick Ex. 11	FRX-AT-03628446	FRX-AT-03628514	10/20/2009	Email: "Revised Settlement agreement"		
DTX-260	McCormick Ex. 15	FRX-AT-03634534	FRX-AT-03634569	11/10/2009	Email: "Revised DRL settlement agreement"		
DTX-261		FRX-AT-03641863	FRX-AT-03641863	5/16/2012	Letter: "Re: General Correspondence: Agreement to Written Request"		
DTX-263		FRX-AT-03642881	FRX-AT-03642895	5/29/2013	Letter: Revised Written Request for pediatric studies for Namenda		
DTX-265	Bray (2017) Ex. 5	FRX-AT-03647101	FRX-AT-03647102	7/7/2011	Letter: "Proposed Pediatric Study Request"		
DTX-266	Carnevale Ex. 4 Carnevale Ex. 15	FRX-AT-03655713	FRX-AT-03655716	9/19/2008	Email: "Proactive Projects and Partner Meetings"		
DTX-295	Ludwig Ex. 9	FRX-AT-03877514	FRX-AT-03877515	4/21/2008	Letter: "Re: Patent Term Extension U.S. Patent Nos. 5,614,560 and 5,061,703"		
DTX-296		FRX-AT-03879201	FRX-AT-03879201	3/18/2009	Document: "Certificate Extending Patent Term"		
DTX-306	McCormick (DRL) Ex. 14	FRX-AT-04229715	FRX-AT-04229718	1/22/2010	Email: "Re: Memantine Hydrochloride legal expenses reimbursement"	402, 403	
DTX-307	McCormick (DRL) Ex. 13	FRX-AT-04231043	FRX-AT-04231046	12/2/2009	Letter: "Re: Memantine Settlement/License Agreements"	402, 403	
DTX-309	Rosen Ex. 7	FRX-AT-04248226	FRX-AT-04248368	12/9/2003	Document: Request for Extension of Patent Term Under 35 U.S.C. § 156		
DTX-316	Carnevale Ex. 9, 9a-c Mears Ex. 9 Solomon Ex. 10	FRX-AT-04340635	FRX-AT-04340641	3/14/2010	Email: "FW: Mylan Term Sheet"		Yes
DTX-320		FRX-AT-04396179	FRX-AT-04396245	4/7/2010	Email: "Accrued Legal Analysis"	402, 403	
DTX-321	Curia (Mylan) Ex. 8	FRX-AT-04408010	FRX-AT-04408041	10/8/2010	Email: "Re: Mylan/Forest Escitalopram Tech Transfer Kickoff Meeting Minutes"		
DTX-323		FRX-AT-04447042	FRX-AT-04447045	2/14/2008	Email: "Collaboration with Forest on Memantine"	402, 403	
DTX-325		FRX-AT-04518672	FRX-AT-04518676	10/21/2011	Document: "Amendment 2 to Distribution Supply Agreemt with Mylan dtd 10-31-11.pdf"		
DTX-328		FRX-AT-04547818	FRX-AT-04547820	3/3/2009	Document: Notice of Final Determination		
DTX-337	Curia (Mylan) Ex. 4	FRX-AT-04593099	FRX-AT-04593307	4/13/2010	Email: "FW: Lexapro Information"		

1:15-cv-07488-CM-RWL
Forest's Phase 1 Exhibit List

Trial Ex. No.	Dep. Ex. #	Beg Bates	End Bates	Date	Doc Description	Objections	Includes Electronic File(s)
DTX-338	Bruno Ex. 6 Curia (Mylan) Ex. 11	FRX-AT-04605364	FRX-AT-04605385	1/20/2011	Agreement: "TECHNICAL/ QUALITY AGREEMENT FOR CONTRACT MANUFACTURE, PACKAGE (ASSEMBLY) TESTING AND BATCH RELEASE"		
DTX-340	Carnevale Ex. 12 Mears Ex. 14	FRX-AT-04616753	FRX-AT-04616756	7/6/2010	Email: "RE: Mylan Lexapro Authorized Generic"		
DTX-341		FRX-AT-04617111	FRX-AT-04617111	1/19/2010	Excel: "Lexapro Generic Analysis - Mylan Share of Generic 40%"		Yes
DTX-342		FRX-AT-04617112	FRX-AT-04617112	1/20/2010	Excel: "Lexapro Generic Analysis HS - Mylan 40% Share - Wt COGS 01 2010.xls"		Yes
DTX-343		FRX-AT-04617116	FRX-AT-04617116	1/19/2010	Excel: "Lexapro Generic Analysis HS - Mylan 50% Share - 01 2010.xls"		Yes
DTX-344		FRX-AT-04617117	FRX-AT-04617117	1/20/2010	Excel: "Lexapro Generic Analysis HS - Mylan 50% Share - Wt COGS 01 2010.xls"		Yes
DTX-345		FRX-AT-04617118	FRX-AT-04617118	3/15/2010	Excel: "Lexapro Generic Analysis HS - Mylan 50% Share - Wt COGS 03 2010 (60-40 Split).xls"		Yes
DTX-346		FRX-AT-04617128	FRX-AT-04617128	1/20/2010	Document: "Forest-Mylan COGS 01 2010.ppt"		
DTX-347		FRX-AT-04617132	FRX-AT-04617132	3/16/2010	Document: "Lexapro Generic Analysis 03 16 2010.PDF"		
DTX-348	Solomon Ex. 11	FRX-AT-04617133	FRX-AT-04617133	3/16/2010	Document: "Lexapro Medicaid Analysis 03 16 2010.PDF"		
DTX-349		FRX-AT-04617597	FRX-AT-04617598	1/14/2010	Email: "FW: LX Medicaid Liability post LOEv2\$.05.xls"		Yes
DTX-350		FRX-AT-04617617	FRX-AT-04617618	1/15/2010	Email: "Re: Authorized Generic Model - Updated"		Yes
DTX-351		FRX-AT-04617623	FRX-AT-04617630	1/15/2010	Email: "Re: Authorized Generic Lexapro/Mylan"		Yes
DTX-352		FRX-AT-04617631	FRX-AT-04617633	1/15/2010	Email: "Re: Authorized Generic Model - Updated"		Yes
DTX-353		FRX-AT-04617653	FRX-AT-04617653	1/19/2010	Email: "Mylan"		
DTX-354		FRX-AT-04617654	FRX-AT-04617660	1/19/2010	Email: "FW: Mylan Mtg Next Week"		Yes
DTX-355		FRX-AT-04617664	FRX-AT-04617668	1/19/2010	Email: "FW: Mylan Mtg Next Week"		Yes
DTX-356		FRX-AT-04617670	FRX-AT-04617674	1/19/2010	Email: "RE: Mylan Mtg Next Week"		Yes
DTX-357		FRX-AT-04617708	FRX-AT-04617713	1/20/2010	Email: " FW: Mylan Mtg Next Week"		Yes
DTX-358		FRX-AT-04617748	FRX-AT-04617750	3/15/2010	Email: "Lexapro Best Price Analysis - Year 2"		Yes
DTX-359	Finchen Ex. 3	FRX-AT-04617753	FRX-AT-04617757	3/16/2010	Email: "RE: Lexapro Best Price Analysis - Year 2"		Yes
DTX-360	Green Ex. 4	FRX-AT-04618301	FRX-AT-04618304	8/12/2010	Email: "RE: Generic Escitalopram"	402	Yes
DTX-361		FRX-AT-04624973	FRX-AT-04624980	11/27/2008	Email: "RE: Memo of Understanding"	402	
DTX-365		FRX-AT-04628192	FRX-AT-04628193	7/1/2010	Document: "Letter Agreement between Forest Laboratories Holdings Limited and H. Lundbeck A/S dated July 1, 2010"		
DTX-367	Bonelli Ex. 6	FRX-AT-04628295	FRX-AT-04628331	1/13/2011	Document: Forest Standard Operating Procedure, Medicaid Government Pricing Methodology		
DTX-379		LPI-NMDA-00001189	LPI-NMDA-00001190	3/25/2015	Letter: "Re: ANDA # 090051; Memantine Hydrochloride Tablets, 5 mg and 10 mg: Response to Information Request"		
DTX-382		LPI-NMDA-00002835	LPI-NMDA-00002837	10/16/2007	Letter: "Re: Original ANDA for Memantine Hydrochloride Tablets, 5 mg and 10 mg"		
DTX-383		LPI-NMDA-00004618	LPI-NMDA-00004620	4/10/2015	Letter: Lupin ANDA 090051 Approval Letter		
DTX-384		LPI-NMDA-00004892	LPI-NMDA-00004905	3/17/2015	Excel: "Minutes of the NPL Meeting 9th Mar 2015_US.xlsx"		
DTX-400	Curia (Mylan) Ex. 30	MYLMEMA_000213	MYLMEMA_000214	10/16/2007	Letter: "RE: MEMANTINE HYDROCHLORIDE TABLETS, 5 MG AND 10 MG ANDA 079225 (Pre- Assigned ANDA Original Application)"		
DTX-402	Curia (Mylan) Ex. 43	MYLMEMA_000343	MYLMEMA_000816	9/21/2007	Document: "Request for In Vivo Bioequivalence Waiver For Memantine Hydrochloride 5 mg and 10 mg Tablet"		
DTX-404	Curia (Mylan) Ex. 36	MYLMEMA_000855	MYLMEMA_000855	N/A	Document: "Mylan: Introduction to Summaries"		
DTX-414	Curia (Mylan) Ex. 37	MYLMEMA_001824	MYLMEMA_001844	N/A	Document: Mylan - Memantine Hydrochloride Tablets, 5 mg and 10 mg	802, 403, 602	
DTX-419	Curia (Mylan) Ex. 32	MYLMEMA_002294	MYLMEMA_002301	10/16/2014	Letter: "RE: RE MEMANTINE HYDROCHLORIDE TABLETS USP, 5 MG AND 10 MG ANDA # 079225 PATENT AMENDMENT"		

1:15-cv-07488-CM-RWL
Forest's Phase 1 Exhibit List

Trial Ex. No.	Dep. Ex. #	Beg Bates	End Bates	Date	Doc Description	Objections	Includes Electronic File(s)
DTX-421	Curia (Mylan) Ex. 2	MYLMEMA_003476	MYLMEMA_003476	4/12/2010	Excel: "Mylan Pharmaceuticals Inc. - 5 Year Financial Plan"		Yes
DTX-422		MYLMEMA_003534	MYLMEMA_003549	9/30/2010	PowerPoint: "Escitalopram Oxalate Tablets U.S. Launch"		
DTX-425		MYLMEMA_003560	MYLMEMA_003560	N/A	Excel: "Manufacturing and Packaging Technical Information Checklist"		
DTX-426	Curia (Mylan) Ex. 6	MYLMEMA_003576	MYLMEMA_003578	10/7/2010	Document: "Meeting Minutes MPI-Forest Escitalopram Kick-off Meeting"		
DTX-427	Curia (Mylan) Ex. 5	MYLMEMA_003597	MYLMEMA_003606	8/18/2010	Presentation: "Mylan Pharmaceuticals Inc. Escitalopram Oxalate Tablets Launch Project Team"		
DTX-428	Curia (Mylan) Ex. 9	MYLMEMA_003612	MYLMEMA_003646	12/22/2010	PowerPoint: "Mylan Pharmaceuticals Inc. Escitalopram Oxalate Tablets Launch Project Team December 22, 2010, Weekly Update"		
DTX-429	Bruno Ex. 18	MYLMEMA_003677	MYLMEMA_003681	12/6/2010	Memo: "Mylan/Forest Escitalopram Tech Transfer Working Group - Core Team Conference Call (Meeting held December 2, 2010) FINAL"		
DTX-430	Curia (Mylan) Ex. 7	MYLMEMA_003688	MYLMEMA_003692	MYLMEMA_003692	Memo: "Mylan/Forest Escitalopram Tech Transfer Working Group - Core Team Conference Call (Meeting held November 18, 2010)"		
DTX-431		MYLMEMA_003696	MYLMEMA_003715	10/8/2010	Document: "Technical/Quality Agreement"		
DTX-445	Silber (Mylan) Ex. 2	MYLMEMA-D-000001	MYLMEMA-D-000001	N/A	Document: Mylan Invoice	802, 402, 403, 901	
DTX-448		ORGENUS0000956	ORGENUS0000959	11/29/2007	Letter acknowledging receipt of ANDA application	402, 403	
DTX-450	Wilk (Orgenus) Ex. 26	ORGENUS0005365	ORGENUS0005369	3/12/2012	Letter: Orgenus ANDA 090044 Final Approval Letter	402, 403	
DTX-461	Benton (Smith Drug) Ex. 19	SDC-NAM-004004	SDC-NAM-004004	12/16/2014	Email: "RE: Acct#1143 Caldwell (Lynn) Item#136515 Namenda 10mg"		
DTX-463	Nadkarni (Sun) Ex. 1	SUN0000008	SUN0000009	10/8/2007	Letter: "Re: ANDA Submission for Memantine Hydrochloride Tablets, 5 mg and 10 mg"		
DTX-464	Nadkarni (Sun) Ex. 8	SUN0007091	SUN0007092	6/18/2014	Email: "memantine - launch delayed by PED"		
DTX-465	Nadkarni (Sun) Ex. 10	SUN0007178	SUN0007183	4/1/2015	Email: "Re: URGENT - Memantine IR Launch status"		
DTX-467	Nadkarni (Sun) Ex. 15	SUN0007277	SUN0007280	5/28/2015	Email: "RE: URGENT ! ! - Memantine - Prebook orders start today 5/28/15"		
DTX-476	Nadkarni (Sun) Ex. 14	SUN0010760	SUN0010760	10/13/2014	Excel: "Memantine IR - forecast & launch data.xlsx"		
DTX-478	Rabinovic (Teva) Ex. 15	TEVANIR-00000095	TEVANIR-00000096	12/22/2014	Email: "RE: ANDA 90052"	402, 403	
DTX-479		TEVANIR-00000123	TEVANIR-00000124	10/16/2007	Letter: "Original Abbreviated New Drug Application Memantine Hydrochloride Tablets, 5 mg and 10 mg"	402, 403	
DTX-480	Cavanaugh (Teva) Ex. 11	TEVANIR-00000162	TEVANIR-00000163	10/29/2015	Document: "Monthly Executive Launch Review"	602, 403, 402, 802, 1006	
DTX-483	Cavanaugh (Teva) Ex. 4	TEVANIR-00000459	TEVANIR-00000463	10/25/2011	Letter: Teva ANDA 090052 Final Approval Letter	402, 403	
DTX-484	Cavanaugh (Teva) Ex. 10	TEVANIR-00000953	TEVANIR-00001006	Jun-15	PowerPoint: "Executive Review of Launches"	30b6, 602, 403, MPT, 402	
DTX-488	Gupta (Torrent) Ex. 4	Torrent-Memantine 00002901	Torrent -Memantine 00002902	5/11/2015	Letter: "Re: ANDA 200155 - Minor Amendment - Final Approval Requested Memantine Hydrochloride Tablets - 5 mg and 10 mg"	402, 403	
DTX-492	Charles Ryan Ex. 9 Farlow Ex. 6	Torrent-Memantine 00008902	Torrent- Memantine 00008909	1986	Document: "Rote Liste 1986"		
DTX-495	Charles Ryan Ex. 6	Torrent-Memantine 00009229	Torrent -Memantine 00009235	N/A	Study: "Effect of Memantine versus dh- Ergotoxine in the case of Cerebral-Organic Psychosyndrome"		
DTX-500	Gupta (Torrent) Ex. 8	Torrent-Memantine 00012102	Torrent -Memantine 00012104	12/9/2015	Email: "RE: Meeting action items from 12/2"	402, 403	
DTX-503	Gupta (Torrent) Ex. 9	Torrent-Memantine 00013734	Torrent -Memantine 00013734	2015	Document: "Memantine Sales Began December 2015"	402, 403	
DTX-504		Torrent-Memantine 00012032	Torrent-Memantine 00012033	8/25/2015	Email: "Re: Memantine"	901, 402, 403	
DTX-505		Torrent-Memantine 00012041	Torrent-Memantine 00012041	8/25/2015	Email: "Memantine"	901, 402, 403	
DTX-507	Venkatesan (Wockhardt) Ex. 16	WOCKHARDT00000006	WOCKHARDT00000008	9/4/2015	Wockhardt: ANDA 090073 Approval Letter	402, 403	

In re: ~~Namenda~~ Direct Purchaser Antitrust Litigation
 1:15-cv-07488-CM-RWL
 Forest's Phase 1 Exhibit List

Trial Ex. No.	Dep. Ex. #	Beg Bates	End Bates	Date	Doc Description	Objections	Includes Electronic File(s)
DTX-515	Venkatesan (Wockhardt) Ex. 19	WOCKHARDT00002150	WOCKHARDT00002169	Dec-13	Document: "Memantine Forecast"	602, 103, 901, 402, 403	
DTX-516	Venkatesan (Wockhardt) Ex. 21	WOCKHARDT00002171	WOCKHARDT00002192	Oct-14	Document: "Memantine Forecast"	402, 403	
DTX-517	Venkatesan (Wockhardt) Ex. 17	WOCKHARDT00002193	WOCKHARDT00002216	Jun-09	Document: "Memantine Forecast"	402, 403	
DTX-518	Solomon Ex. 14 Silber (Mylan) Ex. 5	WSGRMEMA_000100	WSGRMEMA_000107	3/17/2010	Email: "Amendment to Distribution and Supply Agreement"		
DTX-519		N/A	N/A	Aug-17	Pediatric Exclusivity Determinations List, August 2017, FDA		
DTX-530	Gupta (Amneal) Ex. 7	N/A	N/A	4/10/2015	Letter: Amneal's ANDA Approval Letter		
DTX-534		N/A	N/A	Oct-13	Document: Namenda Package Insert		
DTX-632	Jochum Ex. 4	N/A	N/A	N/A	Document: "Timeline for Namenda 'Testing Phase'"	602, 802	
DTX-633		N/A	N/A	N/A	Document: 5,061,703 Patent File Wrapper		
DTX-636	Venkatesan (Wockhardt) Ex. 12	N/A	N/A	N/A	Document: Wockhardt's Business Reasons for Settling	802, 403, 402, 1002, 1006	
DTX-681		FRX-AT-04227159	FRX-AT-04227160	9/1/2010	Email: "Mylan"		
DTX-682		FRX-AT-04251511	FRX-AT-04251513	8/3/2007	Document: "Memorandum of Understanding"		
DTX-683		FRX-AT-04266121	FRX-AT-04266121	4/5/2010	Email: "Namenda settlement payments"		
DTX-686		FRX-AT-04292547	FRX-AT-04292553	1/19/2010	Letter: "Re: Namenda Litigation Invoices for settlement payments"		
DTX-687		FRX-AT-04292554	FRX-AT-04292556	2/18/2010	Letter: "Re: Namenda Litigation Invoices for settlement payments"		
DTX-692		FRX-AT-04617100	FRX-AT-04617103	1/8/2010	Email: "FW: Payment required under memantine settlement agreements"		
DTX-702		FRX-AT-04617113	FRX-AT-04617113	3/18/2010	Excel: "Lexapro Generic Analysis HS - Mylan 40% Share - Wt COGS 03 2010 Years 1 and 2 (70-30 Split) with Lundbeck Share - no generic.xls"		Yes
DTX-703		FRX-AT-04617120	FRX-AT-04617120	1/16/2010	Excel: "LX Medicaid Liability post LOEv5 (JF with full 40% profit share).xls"		Yes
DTX-704		FRX-AT-04617121	FRX-AT-04617121	1/20/2010	Excel: "LX Medicaid Liability post LOEv6 40% Mylan (JF with full 40% profit share) (Wt COGS).xls"		Yes
DTX-705		FRX-AT-04617122	FRX-AT-04617122	1/19/2010	Excel: "LX Medicaid Liability post LOEv6 40% Mylan (JF with full 40% profit share).xls"		Yes
DTX-706		FRX-AT-04617123	FRX-AT-04617123	1/20/2010	Excel: "LX Medicaid Liability post LOEv6 50% Mylan (JF with full 40% profit share) (Wt COGS).xls"		Yes
DTX-707		FRX-AT-04617124	FRX-AT-04617124	1/19/2010	Excel: "LX Medicaid Liability post LOEv6 50% Mylan (JF with full 40% profit share).xls"		Yes
DTX-708		FRX-AT-04617125	FRX-AT-04617125	3/18/2010	Excel: "LX Medicaid Liability post LOEv7 (JF 2 year outlook) with no generic.xls"		Yes
DTX-709		FRX-AT-04617129	FRX-AT-04617129	3/18/2010	Document: "Lexapro Generic Analysis - New Split 03 18 2010.PDF"		
DTX-710		FRX-AT-04617130	FRX-AT-04617130	3/18/2010	Document: "Lexapro Generic Analysis - No Generic in Year 2 03 18 2010.pdf"		
DTX-711		FRX-AT-04617107	FRX-AT-04617107	11/30/2007	Excel: "API Costs.xls"		
DTX-712		FRX-AT-04617109	FRX-AT-04617109	1/20/2010	Excel: "Lexapro COGS Analysis (API-Manufacturing-Packaging).xls"		
DTX-713		FRX-AT-04617110	FRX-AT-04617110	4/12/2010	Excel: "Lexapro Excipient Costs.xls"		
DTX-715		FRX-AT-04617771	FRX-AT-04617775	3/17/2010	Email: "Lexapro Analysis"		Yes
DTX-727		FRX-AT-03655976	FRX-AT-03655984	5/31/2011	Email: "Weekly Report"		
DTX-754		FRX-AT-04623830	FRX-AT-04623832	8/26/2011	Email: "Re: Mylan/Forest Escitalopram Tech Transfer Working Group Core Team Notification of CBE-30 Submission"		
DTX-755		FRX-AT-04624100	FRX-AT-04624109	10/19/2011	Email: "Mylan/Forest Escitalopram Tech Transfer Working Group Core Team Meeting Minutes - October 6 - Final"		
DTX-765	Carnevale Ex. 6	FRX-AT-04340547	FRX-AT-04340548	10/12/2009	Email: "FW: Ceftaroline Letter of Intent & Term Sheet"	402, 403, 404, 802	
DTX-766		FRX-AT-04617531	FRX-AT-04617535	1/7/2010	Email: "FW: Generic Erosion Assumptions"		

Forest's Phase 1 Exhibit List

Trial Ex. No.	Dep. Ex. #	Beg Bates	End Bates	Date	Doc Description	Objections	Includes Electronic File(s)
DTX-774		FRX-AT-04617591	FRX-AT-04617593	1/14/2010	Email: "RE: Authorized Generic Lexapro / Mylan"		
DTX-775		FRX-AT-04617703	FRX-AT-04617707	1/20/2010	Email: "Mylan Mtg Next Week"		
DTX-777		FRX-AT-04566883	FRX-AT-04566943	3/31/2006	Form 10-K for Forest Laboratories, Inc. F/Y/E March 31, 2006	Untimely	
DTX-778		FRX-AT-03515775	FRX-AT-03515828	7/26/2010	Letter from Forest providing to the FTC & DoJ the patent settlement agreement between Forest/ Merz and Mylan; 10/3/2005 Distribution and Supply Agreement between Alphapharm and Forest; Amendment to the Distribution and Supply Agreement between Alphapharm, Mylan and Forest dated 7/21/2010; Agreement between Forest, Merz and Mylan dated 2/18/2010	Untimely	
DTX-779		n/a	n/a	3/31/2007	SEC - Forest Laboratories, Inc. Form 10-K - FYE 2007	Untimely	
DTX-780		n/a	n/a	3/31/2008	SEC - Forest Laboratories, Inc. Form 10-K - FYE 2008	Untimely	
DTX-781		n/a	n/a	3/31/2009	SEC - Forest Laboratories, Inc. Form 10-K - FYE 2009	Untimely	